We’re Buying: GlaxoSmithKline (LSE:GSK)
Today was an incredibly tough day for drug and healthcare giant GSK. It finished up 5.9% down for the day on it’s announcement that it expects to cut its dividend in 2022. I can’t say I’m surprised at this news, though the sharp drop was a hefty blow, especially considering we at CI have holdings …